While the term "healthcare consumerism" has been used since the 1930s, today the term refers to the importance of creating a more patient or consumer-centered experience. Patients want a more integrated, seamless healthcare experience that focuses on their particular needs. Artificial intelligence (A.I.), big tech, and big data give patients more transparency, more choice, and more flexibility across the healthcare ecosystem, which helps to facilitate a more positive healthcare experience. But the use of A.I. and machine learning to improve the patient experience, particularly and most importantly in treatment outcomes, begins long before the application of telemedicine, online appointment setting, digitalization, access to real-time information and price transparency, all of which are being used within the ecosystem with varying degrees of success. Where does healthcare consumerism really begin?

Code Ocean, the leading computational research environment for sharing scientific discoveries, today announced a collaboration that will power AI-driven computational research for oncology-focused drug discovery with Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development. By leveraging Code Ocean's Compute Capsule technology, the move will further power Lantern Pharma's RADR platform for faster, more collaborative discoveries from billions of RADR data points as well as from experimental results and insights from their network of collaborators. Computational researchers today are challenged with analysing big data with too many tools, lack of specialized coding experience, and challenging, cumbersome DevOps processes required to organize and securely share research. Through this collaboration Lantern Pharma is expected to benefit from significant efficiencies in development time and cost as well as increased reproducibility from Code Ocean's platform. The Code Ocean platform will offer an easy to use, collaborative research experience with an integrated development environment, secure repository, and portable Compute Capsule technology for guaranteed reproducibility.

… RADR® artificial intelligence ("A.I.") platform to transform the cost, … A.I. platform and machine learning to discover biomarker signatures …

Exscientia's "Centaur Chemist" AI platform computationally sorts through and compares millions of potential small molecules, looking for a handful to synthesize, test and optimize in the lab before selecting a candidate for clinical trials -- all of which enabled the company to help get a cancer drug into trials in just eight months, compared to a more standard four to five years. Quris is working to speed the trial process by testing drugs on miniaturized organs and tissues on a chip that "represent the full genomic diversity of the potential patient population," notes Bentwich, which in turn generates data that can help train its AI platform to predict the clinical safety and efficacy of novel drugs. Lantern Pharma is partnering with digital health care company Deep Lens to use AI to match the right kind of novel molecule with the right patient profile for clinical trials for accelerated clinical trials. That AI-driven approach "can rescue hundreds of millions of dollars in prior drug development costs by ensuring it's being tested on a very specific patient platform," says Panna Sharma, Lantern Pharma's CEO. Exscientia's "Centaur Chemist" AI platform computationally sorts through and compares millions of potential small molecules, looking for a handful to synthesize, test and optimize in the lab before selecting a candidate for clinical trials -- all of which enabled the company to help get a cancer drug into trials in just eight months, compared to a more standard four to five years.

It's that time when we start to look ahead to what next year holds for the life science sector...Lu Rahman outlines 2020s big medtech players A decade ago the healthcare advances create by AI would have seemed the stuff of dreams. But back in 2018 Theresa May announced plans to use artificial intelligence and data to transform the way certain diseases like cancer. The technology is moving at a pace – this year we heard that a team led by the University of Surrey had filed the first ever patent for inventions autonomously created by AI without a human inventor. Professor Ryan Abbott explained the implications this had for the life science sector: "These filings are important to any area of research and development as well as any area that relies on patents. Patents are more important in the life sciences than in many other areas, particularly for drug discovery. AI has also been used extensively in the drug discovery process for a long time for tasks like screening of compounds and in silico analysis. These tasks can be the foundation for patent filings. "As AI is becoming increasingly sophisticated, it is likely to play an increasing role in R&D including in the life sciences.

NEW YORK--(BUSINESS WIRE)--Lantern Pharma is applying Artificial Intelligence (AI) to tailor multiple promising precision drug programs to the right cancer patients through use of their RADRTM platform (Response Algorithm for Drug Rescue and Positioning). Lantern is disrupting the drug development process using seamless integration of relevant existing data, generation of new clean data closely modeling real world evidence and very focused AI technology application to further model this data and distill into meaningful information that can identify & stratify right patients with high accuracy. Even a small step ahead in the right direction will be a huge leap for the pharma industry. Lantern is currently leading the way in AI directed drug development, recently having fast tracked shelved assets from in-license to out-license within 18 months. Lantern is currently progressing 3 clinical stage drugs in using this technology.